珍寶島(603567.SH):子公司收到《藥品補充申請批準通知書》
格隆匯4月9日丨珍寶島(603567.SH)公佈,公司全資子公司哈爾濱珍寶製藥有限公司(簡稱“哈珍寶”)收到國家藥品監督管理局下發的《藥品補充申請批準通知書》,經公司總經理辦公會審議通過,2024年10月哈珍寶與安徽九洲方圓製藥有限公司(簡稱“安徽九洲方圓”)簽訂了《化學藥品技術轉讓合同》,安徽九洲方圓將包含上述9個品種在內的共計16個化學藥品品規的藥品上市許可持有人轉讓給哈珍寶。上述《藥品補充申請批準通知書》的取得,進一步豐富了公司化藥的產品管線,對於公司高質量發展將起到積極的推動作用。上述事項不會對公司當期經營業績產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.